INMUNE BIO INC. Current Federal Tax Expense (Benefit)
INMUNE BIO INC. (INMB) reported Current Federal Tax Expense (Benefit) of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-11.
Discontinued › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2020-03-11
- INMUNE BIO INC. current federal tax expense (benefit) for fiscal 2019 was $0.00.
- INMUNE BIO INC. current federal tax expense (benefit) for fiscal 2018 was $0.00.
- INMUNE BIO INC. current federal tax expense (benefit) for fiscal 2017 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-11 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-11 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |